Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition - Contract Assets and Liabilities (Details)

v3.21.2
Revenue Recognition - Contract Assets and Liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2021
Dec. 31, 2020
Contract with Customer, Asset, Net [Abstract]    
Current pharma contract assets $ 1,842 $ 1,643
Long-term pharma contract assets 325 290
Total pharma contract assets 2,167 1,933
Capitalized Contract Cost [Abstract]    
Current pharma capitalized commissions 128 185
Long-term pharma capitalized commissions 940 970
Total pharma capitalized commissions 1,068 1,155
Contract with Customer, Liability [Abstract]    
Current pharma contract liabilities 4,497 4,029
Long-term pharma contract liabilities 794 712
Total pharma contract liabilities $ 5,291 $ 4,741